Gold Therapy

Immunology of platelet disorders

Immune-mediated thrombocytopenias (IMTPs) are frequently-occurring haemostatic disorders in clinical medicine. They may be caused by allo-immunity, autoimmunity, or by drug-induced immune mechanism. All IMTPs are caused by antibodies, which may induce increased platelet destruction but may also hinder platelet function. Many different platelet membrane molecules (i.e. antigens) are involved in the immune processes that play a role in IMTP. Much is already known about the structure of these molecules. Notably the alloantigens involved in alloimmune-mediated thrombocytopenia have been quite well studied. Many of these antigens appear to be polymorphic determinants of adhesion molecules of the integrin superfamily, and are also present on cells other than platelets (endothelial cells, fibroblasts, smooth muscle cells). The methodology for studying platelet antigens and antibodies involved in IMTPs has markedly improved in recent years. This has not only led to better diagnostic tests but also to a better understanding of the immunopathogenesis of these diseases. Platelet immunology is scientifically very much alive, and is expected to remain so in the coming years.

Thrombocytopenia associated with auranofin therapy: evidence for a gold-dependent immunologic mechanism

Thrombocytopenia associated with gold therapy is thought to be due to an immune-mediated mechanism. Relatively few patients have been studied so far, and precise details of the pathophysiology of this disease remain undetermined. We report a patient with gold-induced thrombocytopenia resulting from auranofin therapy. The patient's plasma contained platelet-reactive antibodies detectable only in the presence of gold salts. Antibody binding occurred at gold concentrations ranging from 0.01 to 10,000 ng/ml. The binding occurred independently of gold salt used, suggesting that substitution of a different gold preparation in this patient would result in a similar thrombocytopenia. These data support a drug-dependent immune mechanism for platelet destruction.

Evaluation of the renal injury from gold salts and nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis

The urinary excretion of proteins, N-acetyl-3-glucosaminidase and leucine aminopeptidase, was measured in 50 patients with rheumatoid arthritis (RA), of whom 20 subjects were on nonsteroidal anti-inflammatory drugs (NSAIDs) and 30 on gold salts. No pathological changes of the above-mentioned urinary parameters have been observed in the group of RA patients, in comparison with control subjects and patients suffering from osteoarthritis treated with NSAIDs.

Predictive value of mean platelet volume in gold induced thrombocytopenia

In rheumatoid arthritis the mean platelet volume does not alter with the institution of parenteral gold therapy and with long term gold therapy. It appears to have no value in predicting the onset of thrombocytopenia. It may, however, predict a haemorrhagic diathesis once gold induced thrombocytopenia is established.

Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?

We studied 13 patients with rheumatoid arthritis (RA) and gold-induced thrombocytopenia. Platelet-specific autoantibodies of the IgG and often also of the IgM class were detected by immunofluorescence on the patient's platelets and in ether eluates from these platelets. In nine patients we also detected autoantibodies in the serum. The antibodies were unreactive with platelets from patients with Glanzmann's disease in most cases, and were not EDTA dependent. Thus, they had the serological characteristics of true autoantibodies. The reaction of the antibodies with platelets was not influenced by the addition of extra gold. By atomic absorption spectrophotometry we found that the ether eluates, which were often strongly reactive with donor platelets, were free of gold. This indicated that the autoantibodies in the thrombocytopenic patients were not dependent on gold for their reaction. The possibility is raised that gold treatment of rheumatoid arthritis patients induces or enhances the formation of platelet-specific autoantibodies, and that gold-induced thrombocytopenia is a drug-induced autoimmune disease.

Gold-induced immune thrombocytopenia in the dog

In two seven-year studies with gold compounds in dogs of both sexes, thrombocytopenia was observed after 45 to 72 months of dosing in three of 14 and two of 14 dogs in high-dose groups that received 2.4 to 3.6 mg/kg of auranofin per day orally or 0.5 to 2.0 mg/kg of gold sodium thiomalate intramuscularly once every three days, respectively. An immune basis for the disorder was suggested by the apparent consumptive nature of the thrombocytopenia (increased bone marrow megakaryocytes and large peripheral blood platelets), the response to corticosteroid therapy and the demonstration of increased platelet-associated immunoglobulin. The latter was demonstrated with a solid phase radioimmunoassay and by electron microscopy using a staphylococcal protein A-colloidal gold conjugate. Platelet-associated immunoglobulin decreased as the platelet counts rose, and in one dog monitored over periods of steroid-induced remissions and subsequent relapses, the amount of platelet-associated immunoglobulin G correlated inversely with the platelet count (r = 0.82). These findings suggest that the long-term administration of gold compounds in dogs is associated with a dose-dependent incidence of thrombocytopenia, which is immune-mediated and similar to that associated with parenteral chrysotherapy in man. The application of tests for platelet-associated immunoglobulin to canine patients with immune thrombocytopenia should be useful in the diagnosis of the disorder in clinical practice.

Auranofin: a unique oral chrysotherapeutic agent

Auranofin is a chemically unique gold coordination complex with demonstrated antiarthritic properties on oral administration. Its pharmacokinetic and immunologic profiles are distinct from injectable gold compounds. When auranofin is added to a regimen of salicylates and/or a nonsteroidal antiinflammatory drug for the treatment of RA, significant additional therapeutic benefit is observed. Published studies indicate that auranofin given 6 mg per day approaches the efficacy of parenteral gold salts in the treatment of rheumatoid disease. Noticeable improvement in clinical and laboratory parameters of disease activity has been observed by the third month of auranofin therapy. Further benefit occurs in some patients during the remainder of the first year of treatment. In the more than 3,000 patients treated with auranofin, the most frequently reported side effects were gastrointestinal (mainly diarrhea) and mucocutaneous. Most side effects were mild in nature and the withdrawal rate due to all adverse reactions averaged 11%. Auranofin differs from injectable gold by producing more gastrointestinal but fewer mucocutaneous reactions. The severity of these reactions is less with auranofin and causes fewer withdrawals from therapy.

Neurologic complications induced by gold treatment

Two patients developed a Guillain-Barre-like syndrome and a third suffered neuropathy and myokymia during therapy with sodium aurothiomalate. The cumulative dose at the time of development of neuropathy was different in all 3 cases. Evidence for gold toxicity was suggested by clinical, electromyographic, and histologic findings, as well as the disappearance of symptoms and signs on cessation of gold injections.

Maintenance chrysotherapy in rheumatoid arthritis: a comparison of 2 dose schedules

Maintenance treatment with chrysotherapy was given to 44 rheumatoid patients after a total of 1.0 g weekly injections of sodium aurothiomalate. 21 patients continued with 50 mg injections every 2 weeks, and 23 patients received the same dose at 4-week intervals. Their progress was followed over 1 year, after which time their clinical improvements were equally well sustained. Toxicity was greater in those patients receiving fortnightly injections. Five patients suffered a relapse after 8 months. These were not related to the frequency of injections nor to the serum gold levels. There appeared to be no advantage in maintenance injections at fortnightly intervals.

Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine

This study compares the effect of azathioprine with those of gold and chloroquine in early (Class II) rheumatoid arthritis (RA). Thirty-three similar patients with classic or definite RA of less than 5 years duration were randomly entered, 11 into each drug group. Assessment of standard clinical and laboratory measures at 12 and 24 weeks showed significant improvement in all three groups. In general, all three drugs were effective antirheumatic agents with low toxicity. However, because of serious potential toxicity, azathioprine could not be recommended over gold and chloroquine in early RA therapy.